At Grenoble Alpes University Hospital in France, a handful of Crohn’s disease patients have been walking around for the better part of a decade with a small device implanted in their necks that was never built for their condition. The device is a vagus nerve stimulator, the same category of hardware used since the 1990s to treat drug resistant epilepsy. Gastroenterologist Bruno Bonaz and colleagues started implanting them in patients with severe, treatment resistant Crohn’s disease around 2012, on a hunch rooted in immunology rather than neurology. The latest follow-up data on that cohort, tracking patients out to twelve months and in some cases longer, shows something that a lot of bioelectronic medicine research never gets the chance to show: durability. The inflammation markers that dropped after implantation stayed down. Clinical remission that showed up at six months was, for most of the group, still there a year later.
That persistence is the actual news here. Plenty of experimental therapies produce a good first data readout. Few of them in neuromodulation get followed long enough, in real patients, to find out whether the effect fades once the novelty of a new intervention wears off. This one didn’t fade, at least not in the small group tested. That is worth taking seriously, and worth being precise about, because the size of the claim and the size of the trial are badly mismatched.
A French Neurology Trick Borrowed for the Gut
The logic connecting an epilepsy device to a bowel disease runs through the immune system, not the brain. In 2000, Kevin Tracey’s group at what is now the Feinstein Institutes for Medical Research on Long Island published a paper in Nature describing what they called the cholinergic anti-inflammatory pathway. Electrically stimulating the vagus nerve in animals suppressed production of TNF-alpha, the inflammatory signaling molecule that drives tissue damage in conditions ranging from sepsis to rheumatoid arthritis to Crohn’s disease. Cutting the vagus nerve did the opposite: inflammation went up. The vagus, it turned out, isn’t just a conduit for digestion and heart rate. It’s a brake pedal the immune system uses to keep itself in check, and that brake runs through the spleen, where vagal signaling tells macrophages to dial back TNF production.
The same molecule biologic drugs spend billions blocking is the molecule the vagus nerve already knows how to brake.
That overlap with TNF is what makes Crohn’s disease a logical target. Infliximab, adalimumab, and the rest of the anti-TNF drug class built modern inflammatory bowel disease treatment by neutralizing that same molecule from the bloodstream. They work, but they don’t work forever. A meaningful share of patients lose response to anti-TNF therapy over time, develop antibodies against the drug, or never respond in the first place. The proposition behind vagus nerve stimulation in Crohn’s is not that it replaces these drugs. It’s that there might be a way to achieve a similar immunological effect by stimulating the nerve that already does this job, without an infusion, without a self-injection, without the drug cost.
Twelve Months Is Longer Than Most Bioelectronic Trials Get
The Grenoble program started small and stayed small. Bonaz’s team, including gastroenterologist Valérie Sinniger, implanted a repurposed Cyberonics vagus nerve stimulator (the company is now part of LivaNova) in a cohort of patients with Crohn’s disease who had failed conventional therapy. The initial results, published in Neurogastroenterology & Motility in 2016, reported clinical improvement and reduced biological markers of inflammation after six months of stimulation. The follow-up study extended observation to twelve months in the same patients, and that is the data now circulating as evidence the effect holds up rather than wearing off.
What the longer follow-up shows, in plain terms: disease activity scores that fell in the first months of stimulation largely stayed down. Inflammatory markers like CRP and fecal calprotectin, the standard blood and stool tests gastroenterologists use to track gut inflammation without doing a colonoscopy, remained suppressed relative to baseline. Some patients came off or reduced other medications. None of that is a cure, and none of it happened in a trial designed to prove causation in the way a regulator would eventually require. But a year is a long time for an effect to persist in an open label pilot, and that duration is the detail worth paying attention to.
Seven patients followed honestly for a year is worth more than seventy patients followed for six weeks.
What a Small, Unblinded Trial Can and Cannot Tell Gastroenterology
Here is the part that matters and the part that should temper any headline reading too much into this. The Grenoble cohort is small, drawn from a single center, and unblinded. There is no sham stimulation arm. Patients and physicians both know the device is on. Crohn’s disease is also a condition that waxes and wanes on its own, and placebo response rates in IBD trials, measured through endoscopy and biomarkers rather than just symptom questionnaires, are not trivial. None of that means the effect is fake. It means the effect has not yet been isolated from the normal noise of a fluctuating autoimmune disease in a group this size.
The honest comparison is to where rheumatoid arthritis research with the same mechanism stood a decade ago. Paul-Peter Tak and colleagues, working with the company SetPoint Medical, which was built directly on Tracey’s inflammatory reflex research, ran a pilot study published in the Proceedings of the National Academy of Sciences in 2016 showing that implanted vagus nerve stimulation reduced TNF production and disease severity in rheumatoid arthritis patients. That early data read similarly to what Grenoble is now reporting in Crohn’s: small numbers, strong signal, open label design. SetPoint used it to justify a larger, controlled trial program, RESET-RA, and the company has since pursued an FDA Breakthrough Device designation for rheumatoid arthritis and extended its pipeline toward Crohn’s disease and other TNF-driven conditions. That is the template Grenoble’s data needs to follow before anyone should call this proven. It is an argument for running the bigger, blinded trial, not a substitute for one.
| Program | Device Origin | Target Condition | Trial Design | Status |
|---|---|---|---|---|
| Grenoble Alpes University Hospital (Bonaz, Sinniger) | Repurposed epilepsy VNS (LivaNova/Cyberonics hardware) | Crohn’s disease | Small, open label pilot, extended to 12 month follow-up | Published pilot data, no controlled trial yet |
| SetPoint Medical (RESET-RA lineage) | Purpose built miniaturized VNS implant | Rheumatoid arthritis, Crohn’s disease pipeline | Pilot study published 2016; larger controlled program since pursued | FDA Breakthrough Device designation, RA program furthest along |
| Galvani Bioelectronics (GSK / Verily joint venture) | Custom bioelectronic implant research | Inflammatory disease broadly, including RA | Preclinical and early stage research | Scaled back corporate investment since founding in 2016 |
Why a Device Worth Betting On Is Not the Same as a Device Worth Prescribing
The appeal of this approach to gastroenterologists is not mysterious. Anti-TNF drugs are expensive, require ongoing infusions or injections, and a meaningful fraction of patients either don’t respond or stop responding over time. Surgery remains common in Crohn’s disease precisely because medical therapy fails often enough that resection becomes the only option left. An implant that delivers a self-administered dose of nerve stimulation instead of a self-administered dose of monoclonal antibody is an attractive alternative on cost grounds alone, especially for health systems outside the United States that are more sensitive to the price of biologics than American insurers tend to be.
But attractive is not the same as validated, and the gap between those two things is exactly where bioelectronic medicine keeps stalling out. Galvani Bioelectronics, the joint venture GSK and Verily launched in 2016 with a seven year, half billion dollar commitment specifically to build these kinds of devices for inflammatory disease, has not produced an approved therapy, and corporate enthusiasm for the underlying thesis has cooled since. The inflammatory reflex is real. The clinical translation of it into something a regulator signs off on and an insurer pays for has been slower and harder than the founding science promised in 2000.
Grenoble’s data is a reason to keep going, not a reason to declare victory. The next step that actually counts is a multi-site, sham-controlled trial large enough to separate the effect of stimulation from the effect of Crohn’s disease doing what Crohn’s disease does on its own, which is flare and remit unpredictably regardless of what’s implanted in a patient’s neck. Until that trial exists and reads out, the honest description of where this stands is: a small group of patients in France has kept their inflammation down for a year using a nerve stimulator, the biology explaining why is sound, and nobody has yet proven it in the way gastroenterology will eventually require before writing it into guidelines.
The question worth asking isn’t whether the vagus nerve can dial down gut inflammation. Tracey’s lab settled that twenty-five years ago. The question is whether a twelve month signal in seven patients survives contact with a five hundred patient, blinded, multi-center trial, the kind rheumatoid arthritis research is already a decade into running. Crohn’s disease is still waiting for its version of that trial to start.
Credit: Federico Lancellotti on Unsplash